ReviewHuman molecular genetics2011
Helper-dependent adenoviral vectors for liver-directed gene therapy.
Review in Human molecular genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 79 citations in OpenAlex.
- p62/SQSTM1-KEAP1 complex prevents clearance of ubiquitinated Z alpha-1 antitrypsin and aggravates liver proteotoxicity.The Journal of biological chemistry · 2026Article
- Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation.Frontiers in oncology · 2026Review
- Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters.Frontiers in immunology · 2024Article
- Cell and gene therapy for kidney disease.Nature reviews. Nephrology · 2023Review
- Mitochondrial dysfunction reactivates α-fetoprotein expression that drives copper-dependent immunosuppression in mitochondrial disease models.The Journal of clinical investigation · 2023Article
- Review
- Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy.Pathogens (Basel, Switzerland) · 2022Review
- Gene therapy approaches for equine osteoarthritis.Frontiers in veterinary science · 2022Review
- Current development in adenoviral vectors for cancer immunotherapy.Molecular therapy oncolytics · 2021Review
- Hepatic glutamine synthetase augmentation enhances ammonia detoxification.Journal of inherited metabolic disease · 2019Article
- Modulation of immune responses in lentiviral vector-mediated gene transfer.Cellular immunology · 2019Review
- Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Journal of inherited metabolic disease · 2017Review
- Review
- In Silico Modeling of Liver Metabolism in a Human Disease Reveals a Key Enzyme for Histidine and Histamine Homeostasis.Cell reports · 2016Article
- Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1.Gene therapy · 2016Article
- Gene Therapy for Metabolic Diseases.Translational science of rare diseases · 2016Article
- Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.Gene therapy · 2015Article
- CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.Scientific reports · 2015Article
- High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors.Molecular therapy. Methods & clinical development · 2015Article
- Recent advances in gene therapy for lysosomal storage disorders.The application of clinical genetics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Helper-dependent adenoviral (HDAd) vectors devoid of all viral-coding sequences are promising non-integrating vectors for liver-directed gene therapy because they have a large cloning capacity, can efficiently transduce a wide variety of cell types from various species independent of the cell cycle and can result in long-term transgene expression without chronic toxicity. The main obstacle preventing clinical applications of HDAd for liver-directed gene therapy is the host innate inflammatory response against the vector capsid proteins that occurs shortly after intravascular vector administration resulting in acute toxicity, the severity of which is dependent on vector dose. Intense efforts have been focused on elucidating the factors involved in this acute response and various strategies have been investigated to improve the therapeutic index of HDAd vectors. These strategies have yielded encouraging results with the potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.